Loading clinical trials...

RECRUITING

Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP)

Comparison of Acetoacetate and Acetate Kidney Uptake in Patients With Chronic Kidney Failure Measured by Positron Emission Tomography : the RENO-TEP Project

NCT05968391•Université de Sherbrooke

View on ClinicalTrials.gov

Summary

The objective of this study is to nake a comparison between 11c-acetate and 11c-acetoacetate kidney uptake in chronic kidney failure patients.

Detailed Description

Chronic kidney failure patients will be ask to perform two positron emission tomography scan during the same day. One, with a 11C-Acetate Tracer and the other with 11C-Acetoacetate. The results will allow to determine the difference between the two tracers and will ultimately be compared with precedent results of healthy controls.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•BMI between 18.5 and 40
•Kidney failure if GFR betweem 30 and 60 mL/min/1.73m2
•Stable medication for at least 4 weeks

Exclusion Criteria

•1. Receive cytotoxic therapy for primary or secondary kidney disease within 6 months prior to enrollment
•2. Organ Transplant History
•3. Class IV congestive heart failure (New York Heart Association)
•4. Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrollment
•5. Coronary revascularization (percutaneous coronary intervention or arterial bypass) or valve repair/replacement within 12 weeks of enrollment or is scheduled to undergo one of these procedures within 4 weeks of enrollment
•6. Any condition outside the realm of renal and cardiovascular disease, such as, but not limited to, malignancy, with a life expectancy of less than 2 years in the clinical judgment of the investigator
•7. Active malignancy requiring treatment at Visit 1 (except successfully treated basal or squamous cell carcinoma).
•8. Hepatic impairment (aspartate transaminase or alanine transaminase \>3x upper limit of normal; or total bilirubin \>2x upper limit of normal at time of enrollment
•9. Pregnancy or lactation
•10. Adherence to a ketogenic diet, consumption of ketogenic products or supplements or intermittent fasting or other diet or supplements that may significantly increase ketones in the past two months.
+4 more criteria

Locations (1)

Centre de recherche sur le vieillissement

Sherbrooke, Quebec, Canada

Key Dates

Start Date

February 2, 2024

Primary Completion Date

December 15, 2024

Completion Date

June 15, 2025

Last Updated

June 3, 2024

Enrollment

ESTIMATED participants

Conditions

Kidney Failure, Chronic

Interventions

PET scan metabolic day

RADIATION

Contacts

Valerie St-Pierre, MSc

CONTACT

8197802220 valerie.R.st-pierre@usherbrooke.ca

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

NCT06314503

Renal Insufficiency, ChronicKidney Failure, Chronic+1 more

View study

RECRUITINGNA

Effects of Royal Jelly Supplementation in Chronic Kidney Disease

NCT06438445

Kidney Failure, ChronicOxidative Stress+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP)

Inclusion Criteria

Exclusion Criteria

First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

Effects of Royal Jelly Supplementation in Chronic Kidney Disease

Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients

DePTH: De-emphasize PTH

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)